SINK SIDE
NOTESSKIN-CARE DECISIONPRACTICAL CALL

U.S. ROUTINE CONTEXT · PRACTICAL CALL

Make an occasional blemish less visible without buying an acne-treatment claim

Choose a cosmetic appearance or coverage option for an occasional spot while keeping the treatment boundary clear.

NOTE 01

OUR SINK-SIDE CALL

The route we would take.

Protect or conceal an occasional blemish without attacking it

NOTE 02

Where the call changes.

CHOOSE DIFFERENTLY WHEN

  • Aggressive spot stacking can irritate more than the original blemish.
  • A cosmetic label should not delay care for persistent or severe breakouts.

WHAT WE ARE NOT CLAIMING

  • The full protocol, comparator, primary criteria, sample size and profile, dispersion, and complete report are often not public.

NOTE 03

HOW TO READ THIS NOTE

Evidence without theater.

This page makes an editorial call from documented context. It does not claim a product was owned, used, ranked, or independently tested. Manufacturer statements never become our results.

EVIDENCE TRAIL

What the sources carry — and what the desk decides.

The linked sources support product status, labeling, or professional boundaries. They do not prove the editorial winner and they do not stand in for an owned test.

EDITORIAL JUDGMENT

Protect or conceal an occasional blemish without attacking it

A reasoned course of action; not a product result measured by the source.
BOUNDARY OF THE CALL

Aggressive spot stacking can irritate more than the original blemish.

The full protocol, comparator, primary criteria, sample size and profile, dispersion, and complete report are often not public.

Primary and professional sources in the record

  1. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)U.S. Food and Drug Administration
  2. Cosmetics Labeling ClaimsU.S. Food and Drug Administration
  3. Summary of Cosmetics Labeling RequirementsU.S. Food and Drug Administration
  4. 21 CFR Part 701 — Cosmetic LabelingOffice of the Federal Register / eCFR
  5. 21 CFR Part 740 — Cosmetic Product Warning StatementsOffice of the Federal Register / eCFR
  6. FDA Adverse Event Monitoring System (AEMS)U.S. Food and Drug Administration
Data and test conditions still required
Product function and category

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Ingredient list for the current version

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Body area and directions

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Wear, transfer, and migration

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Regulatory status and applicable labeling

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Tolerance protocol and stop criteria

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Assess targeted coverage under fixed conditions

Define and retain the conditions, date, material, and outcome before presenting any owned observation.

Classify status by intended use and claim

Define and retain the conditions, date, material, and outcome before presenting any owned observation.

Separate cosmetic skin care from medical review

Define and retain the conditions, date, material, and outcome before presenting any owned observation.